Dacogen FDA Approval History
FDA Approved: Yes (First approved May 2, 2006)
Brand name: Dacogen
Generic name: decitabine
Dosage form: for Injection
Company: MGI Pharma Inc. and SuperGen Inc.
Treatment for: Myelodysplastic Diseases
Dacogen (decitabine) is a hypomethylating agent indicated for treatment of patients with myelodysplastic syndromes (MDS), a cancer of the bone marrow.
Development timeline for Dacogen
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.